CD4(+) T-lymphocytopenia and systemic immune activation in patients with primary and secondary liver tumours

Citation
B. Melichar et al., CD4(+) T-lymphocytopenia and systemic immune activation in patients with primary and secondary liver tumours, SC J CL INV, 61(5), 2001, pp. 363-370
Citations number
35
Categorie Soggetti
Research/Laboratory Medicine & Medical Tecnology","Medical Research General Topics
Journal title
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION
ISSN journal
00365513 → ACNP
Volume
61
Issue
5
Year of publication
2001
Pages
363 - 370
Database
ISI
SICI code
0036-5513(2001)61:5<363:CTASIA>2.0.ZU;2-K
Abstract
Using flow cytometry, we evaluated peripheral blood leucocyte subsets in 84 patients with primary and secondary liver cancer. The patients had signifi cantly lower absolute (659 +/- 386 vs, 906 +/- 360 cells per mul, p=0.004) numbers of CD3(+)CD4(+), relative (9 +/-5 vs. 12 +/-4%, p=0.02) and absolut e (154 +/- 115 vs. 221 +/- 83 cells per mul, p=0.02) numbers of CD8(+)CD28( +), absolute numbers of CD3(+) and relative and absolute numbers of CD19(+) . Relative and absolute numbers of CD3(+)DR(+), CD3(+)CD69(+) and CD14(+)CD 16(+) cells were significantly elevated in patients compared to controls. T he phenotype was similar in 54 patients exposed to chemotherapy compared to 30 untreated patients. Urinary neopterin, a marker of systemic immune acti vation, was significantly higher in patients with liver tumours compared to controls. A negative correlation was observed between urinary neopterin an d the absolute numbers of CD3(+)CD4(+) (Spearman rank correlation coefficie nt, rs= -0.54, p<0.0025) and CD19(+) (rs= -0.49, p<0.01) in untreated patie nts. We conclude that, independently of prior chemotherapy, patients with l iver present with markedly decreased numbers of CD3(+)CD4(+) lymphocytes as well as with other abnormalities of peripheral blood leukocyte phenotype. Similar to patients with human immunodeficiency virus infection, the decrea se in CD3(+)CD4(+) lymphocytes is associated with systemic immune activatio n.